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MaBACKGROUND Patients with chronic heart failure (HF) secondary to left ventricular systolic dysfunction (LVSD) are
frequently deﬁcient in vitamin D. Low vitamin D levels are associated with a worse prognosis.
OBJECTIVES The VINDICATE (VitamIN D treatIng patients with Chronic heArT failurE) study was undertaken to
establish safety and efﬁcacy of high-dose 25 (OH) vitamin D3 (cholecalciferol) supplementation in patients with chronic
HF due to LVSD.
METHODS We enrolled 229 patients (179 men) with chronic HF due to LVSD and vitamin D deﬁciency
(cholecalciferol <50 nmol/l [<20 ng/ml]). Participants were allocated to 1 year of vitamin D3 supplementation (4,000 IU
[100 mg] daily) or matching noncalcium-based placebo. The primary endpoint was change in 6-minute walk distance
between baseline and 12 months. Secondary endpoints included change in LV ejection fraction at 1 year, and safety
measures of renal function and serum calcium concentration assessed every 3 months.
RESULTS One year of high-dose vitamin D3 supplementation did not improve 6-min walk distance at 1 year, but was
associated with a signiﬁcant improvement in cardiac function (LV ejection fraction þ6.07% [95% conﬁdence interval (CI):
3.20 to 8.95; p < 0.0001]); and a reversal of LV remodeling (LV end diastolic diameter -2.49 mm [95% CI: -4.09 to
-0.90; p ¼ 0.002] and LV end systolic diameter -2.09 mm [95% CI: -4.11 to -0.06 p ¼ 0.043]).
CONCLUSIONS One year of 100 mg daily vitamin D3 supplementation does not improve 6-min walk distance but
has beneﬁcial effects on LV structure and function in patients on contemporary optimal medical therapy. Further
studies are necessary to determine whether these translate to improvements in outcomes. (VitamIN D Treating
patIents With Chronic heArT failurE [VINDICATE]; NCT01619891) (J Am Coll Cardiol 2016;67:2593–603)
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ABBR EV I A T I ON S
AND ACRONYMS
1,25 (OH)2 vitamin D3 =
calcitriol
25(OH) vitamin D2 =
ergocalciferol
25 (OH) vitamin D3 =
cholecalciferol
AF = atrial ﬁbrillation
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
HF = heart failure
LV = left ventricular
PTH = parathyroid hormone
SR = sinus rhythm
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2594Patients suffering from cardiovascular
disease are frequently deﬁcient in the steroid
hormone vitamin D, and vitamin D deﬁciency
has been shown to be associated with the
development of chronic HF in a number of
studies (6–10). Approximately 90% of chronic
HF patients have hypovitaminosis D (11),
even in sunny climates (12). The agent has a
range of pleiotropic effects that in the setting
of chronic HF may impact on disease severity
(13,14), but despite this, clinical trials exam-
ining vitamin D supplementation in chronic
HF patients have to date been inconclusive
(15,16).SEE PAGE 2604The aim of the VINDICATE (VitamIN D
treatIng patients with Chronic heArT failurE) study
was to describe the safety and efﬁcacy of long-term,
high-dose vitamin D3 supplementation on submaxi-
mal exercise capacity and cardiac function in patients
with chronic HF due to LVSD.
METHODS
STUDY POPULATION. VINDICATE was a randomized
placebo-controlled double-blind trial of vitamin D
supplementation in vitamin Ddeﬁcient chronic HF
patients on optimal medical therapy. Patients
were eligible if they had stable (>3 months) New
York Heart Association functional class II or III symp-
toms, a left ventricular ejection fraction (LVEF) #45%
on maximally tolerated medical therapy (>3 months)
and a 25(OH) vitaminD level of<50nmol/l (<20 ng/ml).
Patients were ineligible if they were taking or had
taken calcium or other vitamin supplements in the
last 3 months; if their chronic HF was due to un-
treated valvular heart disease, anemia or thyrotoxi-
cosis; if they had existing indications for vitamin D
supplementation (e.g., previous osteoporotic fracture
or symptoms of osteomalacia); if they had a history of
primary hyperparathyroidism, sarcoidosis, tubercu-
losis or lymphoma, a cholecalciferol concentration at
the time of screening >50 nmol/l (20 ng/ml); or if
there was signiﬁcant renal dysfunction (estimated
glomerular ﬁltration rate <30 ml/min).
ALLOCATION AND INTERVENTION. Patients enrolled
into VINDICATE were allocated in blocks of 20 using
minimization balancing for etiology of chronic HF
(ischemic/non-ischemic), diabetes mellitus, sex,
chronic obstructive pulmonary disease (requiring
use of regular bronchodilators), and ethnic origin
(Caucasian/non-Caucasian). Each participant was
asked to take 2 tablets per day providing either a totalof 100 mg cholecalciferol (4,000 IU daily) or placebo
(Cultech, Port Talbot, Wales, United Kingdom).
The supplement and dose were chosen based upon
guidelines for studies of vitamin D supplementation
(17). These guidelines suggest that studies should:
1) aim to replace physiological requirements, supple-
menting between 75 and 250 mg/day; 2) last at least 9
months; 3) supplement with vitamin D3 (not D2);
4) assay supplements for potency; 5) include a regular
serum measurement of 25(OH)D3 levels; and 6) aim to
achieve serum levels in patients on active therapy
between 100 and 160 nmol/l (40 ng/ml to 64 ng/ml).
Also, on the basis of recent data demonstrating the
adverse effect of hyperparathyroidism in chronic HF
(18), we chose a dose likely to suppress parathyroid
hormone (PTH) release. Our proof of concept study,
using the same inclusion and exclusion criteria and
protocol as VINDICATE, had previously demonstrated
the efﬁcacy of 4,000 IU daily to achieve positive
remodeling with signiﬁcant reductions in left ven-
tricular end-diastolic volume (LVEDV), left ventricular
end-systolic volume (LVESV), and left ventricular end-
diastolic dimension (LVEDD). The consort diagram and
results from this study are presented in online sup-
plementary datasets (Online Figure 1, Online Tables 1
and 2). A simple linear model-based trend test from
this study demonstrated a signiﬁcant decrease in PTH
over the year (p¼0.0095) in those allocated vitamin D,
with no such trend in patients allocated to the placebo
arm (p ¼ 0.977) (Online Figure 2) (19).
OUTCOME VARIABLES. The pre-speciﬁed primary
endpoint in VINDICATE was the difference in
change in 6-min walk test distance (6MWT) (base-
line to 12 months) between the 2 groups. Key
pre-speciﬁed secondary endpoints included cardiac
structure and function, and safety endpoints of
serum calcium concentration, renal function, and
vitamin D levels. Hypervitaminosis D was deﬁned as
25(OH)D3 >200 nmol/l (80 ng/ml), and hypercalce-
mia as >2.6 nmol/l (10.4 mg/dl).
STUDY PROCEDURES. At baseline each patient per-
formed a 6MWT according to standard criteria (20).
Each patient also underwent echocardiography and
blood sampling for serum calcium, serum creatinine,
vitamin D, and PTH levels. Patients were also invited
to undergo cardiac magnetic resonance (CMR) imag-
ing to measure LV volumes. Subsequent visits took
place at 3, 6, 9, and 12 months and blood draws were
repeated at each visit for safety data.
SERUM BIOCHEMISTRY. Serum 25(OH)D2 and 25(OH)D3
were analyzed by tandem mass spectrometry. Sam-
ples were prepared using a protein precipitation
reagent containing deuterated cholecalciferol. The
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2595supernatant was analyzed on an API5000 LC-MS/MS
(AB SCIEX, Warrington, United Kingdom) in
atmospheric-pressure chemical ionization mode. The
inter-assay coefﬁcient of variability was <10% at all
concentrations ranging from 12 nmol/l to 159 nmol/l
(4.8 ng/ml to 63.7 ng/ml). Ergocalciferol and cholecal-
ciferol concentrations were summed and reported as
total 25(OH)D.We deﬁned deﬁciency and insufﬁciency
of vitamin D concentrations as <50 nmol/l (20 ng/ml)
and <75 nmol/l (30 ng/ml), respectively (21,22). We
also measured serum calcium, creatinine, and PTH
(Siemens Advia and Centaur, Siemens Healthcare
Diagnostics, Camberley, United Kingdom). To conﬁrm
effective conversion of the supplement, we also
measured 1,25(OH)D3 by radioimmunoassay (IDS,
Boldon, United Kingdom) at baseline and 12 months.
ECHOCARDIOGRAPHY. Echocardiography was per-
formed on all patients at baseline and LV function was
assessed according to European Society of Cardiology
criteria using Simpson’s biplane measure to deter-
mine LVEF (23). Echocardiography was repeated at 12
months. Echocardiograms at both time points were
analyzed ofﬂine at the end of the study by 2 senior
echocardiographers blinded to patient treatment.
CMR IMAGING. CMR studies were performed on
dedicated 1.5-T or 3-T CMR systems (Philips Health-
care, Best, the Netherlands). The same system was
used for baseline and follow-up studies (at 12 months)
of individual patients. A multislice multiphase
data set covering the entire left ventricle in 10 to
12 short axis slices was acquired using a validated
2-dimensional balanced steady-state free precession
pulse sequence (TR 2.8 ms, TE 1.4 ms, ﬂip angle 55,
spatial resolution 2.0 mm  2.0 mm  10 mm, no
interslice gap, 30 phases/cardiac cycle, 1 slice per
breath-hold). Ofﬂine analysis by an experienced CMR
observer using QMASS V7.0 software (Medis, Leiden,
the Netherlands) blinded to study allocation derived
end-diastolic and end-systolic LV volumes and LVEF.
SAMPLE SIZE. VINDICATE was powered to provide
information on the patient-oriented outcome of
6MWT. A trial of iron supplementation in a similar
patient group had demonstrated that improvements
of 30 m to 40 m could be expected with this type of
intervention (24). We assumed, based upon our pre-
liminary data from a pilot study (19), that there would
be a change between the 2 groups at 12 months of
30 m. The SD of change in 6MWT was estimated from
these data; the upper limit of the 80% conﬁdence in-
terval (CI) (estimated using bootstrapping) was used
in these calculations to allow for the small sample size
in the proof of concept. This determined that 210 pa-
tients were required to have 90% power to show adifference in change in 6MWT of 28 m or more with 5%
signiﬁcance (SD ¼ 62). We aimed to recruit 230 pa-
tients (115 per group) to allow for w10% dropout.
STATISTICAL ANALYSIS. Differences in baseline
variables between allocations were tested using Stu-
dent t tests (continuous data) or the chi-square test
(categorical data). The analysis of primacy for the
main efﬁcacy endpoints was based on analysis of
covariance linear models relating differences in the
ﬁnal walk distance and imaging variables by treat-
ment allocation, adjusting for baselines values and
reported with 95% CIs (25). All signiﬁcance tests were
2-sided and called signiﬁcant at the 5% level. All
analyses were conducted in Stata (version 14,
StataCorp., College Station, Texas).
ETHICAL AND SAFETY CONSIDERATIONS. A single
unblinded observer with no involvement in the
patients’ care or study follow-up (J.H.B.) reviewed
each vitamin D result at each time point for safety.
An agreed operating procedure for any subject
who developed a serum vitamin D concentration
>200 nmol/l (80 ng/ml) involved reducing the dose
of treatment from 2 to 1 tablets per day to maintain
patient blinding.
RESULTS
We enrolled 229 patients into VINDICATE. Six
patients were found to be ineligible at the baseline
visit, leaving 223 patients randomized to treatment.
Figure 1 describes patient recruitment and loss to
follow-up. A total of 163 patients completed the
study. Baseline characteristics divided by treatment
allocation are shown in Table 1. There were no
important clinical differences at baseline between
patients completing the study and those who drop-
ped out. The 2 groups of completing participants were
balanced for baseline clinical variables (Table 1).
The vitamin D3 supplement was well-tolerated and
achieved sustained normal serum 25(OH)D concen-
trations by 3 months post-randomization, indicating
excellent adherence to treatment (Figure 2). Patients
in the placebo arm had lower median concentra-
tions of 25(OH)D at 12-months post-randomization,
(24.5 nmol/l; range: 10.0 to 81.8 nmol/l [9.8 ng/ml;
range: 4 to 32.7 ng/ml]) than patients in the active
supplement arm (115 nmol/l; range: 17.8 to 193 nmol/l
[46 ng/ml; range: 7.1 to 77.2 ng/ml]; p < 0.0001) con-
ﬁrming the effectiveness of the vitamin D supple-
mentation in normalizing vitamin D levels. The
supplement also effectively normalized 1,25 (OH)2
vitamin D3 (calcitriol) levels to 121 pmol/l (range: 40 to
331 pmol/l [46.5 pg/ml; range: 15.4 to 127.3 pg/ml]) at
12 months and also suppressed PTH levels, leading to
FIGURE 1 Consort Diagram Demonstrating Patient Enrollment and Disposition for VINDICATE
Assessed for eligibility
(n=273)
Excluded (n=44)
  Not meeting inclusion criteria (n=12)
  Declined to participate (n=32)
Excluded at baseline
visit (n=6)
Enrolled (n=223)
Lost to follow-up (n=26)
Death or deterioration (n=14), patient
withdrawal (n=10), side effects (n=2)
Lost to follow-up (n=30)
Death or deterioration (n=14), patient
withdrawal (n=13), side effects (n=3)
Allocated to placebo (n=109)
Analyzed (n=83) Analyzed (n=80)
Allocated to Vitamin D (n=114)
VINDICATE ¼ VitamIN D treatIng patients with Chronic heArT failurE.
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2596lower PTH levels in subjects allocated vitamin D
(8.70 pmol/l; range: 1.28 to 22.2 pmol/l [82 ng/ml,
range: 12 to 209 ng/ml]) than those allocated placebo
(10.80 pmol/l; range: 2.80 to 53.10 pmol/l [102 ng/ml,
range: 26 to 499 ng/ml]); analysis of covariance
difference in mean change was -3.63 pmol/l, 95% CI:
-5.24 to -2.03 pmol/l (-34 ng/ml, 95% CI: -49 to
-19 ng/ml); p < 0.0001.
No patient was observed to suffer hypervitamin-
osis D according to our pre-speciﬁed safety con-
centration of 200 nmol/l (80 ng/ml) 25(OH)D and
no subject required a down-titration of dose. One
patient with borderline hypercalcemia at baseline
(2.66 mmol/l [10.64 mg/dl]) had persistent hypercal-
cemia throughout the study, and 1 other patient with
hypercalcemia at 3 months (2.73 mmol/l [10.9 mg/dl])
had a normal calcium level by 6 months and
throughout the remainder of the study (Figure 2).
There was no concerning change in renal function
(Figure 2) and there were no study drug-related
admissions or adverse events. Twelve months of4,000 IU of cholecalciferol did not improve or preserve
6MWT distance in chronic HF patients (Figure 3).
At 12 months, patients in the vitamin D arm had a
greater improvement in echocardiographic measures
of LV function compared with patients randomized to
placebo. Changes in the treatment versus placebo arms
were as follows: for LVEF þ7.65% (95% CI: 5.21% to
10.09%) and þ1.36% (95% CI: -0.38% to 3.11%),
respectively (p<0.0001); for LVEDD -2.45mm (95%CI:
-3.70 to -1.21 mm) and 0.08 mm (95% CI: -1.25 to 1.10
mm), respectively (p ¼ 0.002); and for LVESD were
-2.72 mm (95% CI: -4.52 to -0.92 mm) and -0.99 mm
(95% CI: -2.31 to 0.33 mm), respectively (p ¼ 0.043).
Changes in LV volumes in the treatment versus the
placebo arms were: LVEDV -16.47 ml (95% CI: -25.71 to
-7.22 ml) and -3.83 ml (95% CI: -13.36 to 5.70 ml),
respectively (p ¼ 0.04); and LVESV -18.77 ml (95% CI:
-25.96 to 9.59 ml) and -8.49 ml (95% CI: -17.98 to
1.01 ml), respectively (p ¼ 0.041) (Table 2, Figure 3).
There was a dose-response relationship between the
increase in vitamin D levels and the increase in LVEF
TABLE 1 Patient Demographics (VINDICATE) at Randomization:
Intention-to-Treat Population
Total
(n ¼ 163)
Placebo
(n ¼ 83)
Vitamin D
(n ¼ 80)
Male 129 (79.1) 62 (74.7) 67 (83.8)
Age, yrs 68.7  13.10 69.0  13.78 68.5  12.45
Caucasian 146 (90.0) 74 (89.0) 72 (90.0)
Etiology
Ischemic heart disease 94 (57.7) 50 (60.2) 44 (55.0)
Nonischemic cardiomyopathy 61 (37.4) 29 (34.9) 32 (40.0)
Valvular heart disease 8 (4.9) 4 (4.8) 4 (5.0)
Diabetes mellitus 37 (22.7) 20 (24.1) 17 (21.3)
BMI, kg/m2 30.0  11.41 30.3  14.36 29.8  7.26
NYHA functional class
II 145 (89.0) 71 (85.5) 74 (92.5)
III 18 (11.0) 12 (14.5) 6 (7.5)
Beta blockers 155 (95.1) 79 (95.2) 76 (95.0)
ACEi/ARB 150 (92.0) 76 (91.6) 74 (92.5)
Furosemide dose, mg/day 61.4  46.38 64.4  52.07 58.6  41.00
Digoxin 29 (18.0) 15 (18.3) 14 (17.7)
Spironolactone 83 (51.2) 41 (50.0) 42 (52.5)
Device (ICD or CRT) 48 (29.5) 27 (32.5) 21 (26.3)
Atrial ﬁbrillation, 68 (45.0) 33 (42.9) 35 (47.3)
Baseline heart rate, beats/min 70.5  13.10 72.7  14.72 68.2  10.86
Systolic BP, mm Hg 120.3  20.81 122.9  22.44 117.6  18.74
Diastolic BP, mm Hg 71.2  13.21 72.8  14.96 70.0  10.99
6-min walk test, m 292.9 (120.35) 283.7 (116.84) 302.2 (123.81)
LVEF % 26.1  10.68 26.5  10.62 25.6  10.80
LVEDD, mm 57.8  7.58 58.0  6.49 57.6  8.62
LVESD, mm 50.3  8.50 50.7  7.58 49.8  9.42
LVEDV, ml 163.0  66.60 164.1  60.07 161.8  73.58
LVESV, ml 115.4  59.39 119.4  53.30 111.0  63.58
25(OH) Vitamin D, nmol/l 37.3  22.56 36.4  20.24 38.2  24.81
Parathyroid hormone, pmol/l 11.4  8.09 11.7  7.50 11.0  8.75
Creatinine, mmol/l 96  29.3 94.4  29.42 96.6  29.26
Values are n (%) or mean  SD. Conversion factors: vitamin D nmol/l $ 0.4 ¼ ng/ml; creatinine mmol/l $ 0.11 ¼
mg/dl; calcium mmol/l $ 4 ¼ mg/dl; parathyroid hormone pmol/l $ 9.4 ¼ pg/ml.
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ aldosterone receptor blocker; BMI ¼ body mass index;
BP ¼ blood pressure; CRT ¼ cardiac resynchronization therapy; ICD ¼ implantable cardioverter deﬁbrillator;
LVEDD ¼ left ventricular end-diastolic diameter; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left
ventricular ejection fraction; LVESD ¼ left ventricular end-systolic diameter; LVESV ¼ left ventricular end-
systolic volume; NYHA ¼ New York Heart Association functional class; VINDICATE ¼ VitamIN D treatIng
patients with Chronic heArT failurE.
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2597(coefﬁcient 0.04; p ¼ 0.023) and decrease in LVEDV
(coefﬁcient -0.02; p ¼ 0.035).
Enrollment into VINDICATE did not mandate CMR
imaging, and one-third of patients in VINDICATE had
cardiac devices incompatible with CMR imaging. Only
69 patients volunteered to undergo baseline CMR
scanning. The CMR data are further limited as a result
of withdrawal or death during follow-up (n¼8), device
implantation between baseline and follow-up (n ¼ 2
implantable cardioverter deﬁbrillators), patient
refusal to undergo a second scan (n¼ 17), and technical
problems with the second scan, such that we only had
34 patients with serial CMR images. Baseline charac-
teristics of these patients are shown in Online Table 3.
Patients agreeing to serial CMR scans were younger
(61.5 years [range: 36.7 to 84.8 years] vs. 71.3 years
[range: 28.1 to 92.3 years]; p < 0.0001) had better
renal function (creatinine: 86 mmol/l [range: 43 to
114 mmol/l] vs. 102 mmol/l [range: 48 to 245 mmol/l];
p ¼ 0.007) and were non-signiﬁcantly less deﬁcient in
25-(OH) vitamin D at baseline (43.9 nmol/l [range: 10.0
to 90.4 nmol/l] vs. 35.94 nmol/l [range: 10.0 to
111.0 nmol/l] or 17.6 ng/ml [range: 4.0 to 36.2 ng/ml] vs.
14.4 ng/ml [range: 4.0 to 44.4 ng/ml]; p ¼ 0.07), but
were otherwise similar to patients who declined CMR
scanning including the change in vitamin D from
baseline to completion (p ¼ 0.64). The data from serial
CMR scans showed improvements in cardiac function
with vitamin D, but were not statistically signiﬁcant
possibly due to insufﬁcient statistical power: for LVEF
4.12% (95% CI: -0.11% to 8.35%) versus 1.19% (95% CI:
-3.20% to 5.59%; p ¼ 0.317), for LVEDV -26.12 ml
(95% CI: -63.27 to 11.04 ml) versus –0.10 ml (95% CI:
-12.88 to 13.07 ml; p ¼ 0.168) and for LV -29.61 ml
(95% CI: -72.40 to 13.18 ml) versus –1.36 ml (95% CI:
-19.19 to 16.48 ml; p ¼ 0.206). There was however, a
dose response relationship in our CMR data, with a
relationship between increases in vitamin D and
reductions in LVEDV (coefﬁcient -0.19; p ¼ 0.050) and
LVESV (coefﬁcient -0.20; p ¼ 0.083).
DISCUSSION
VINDICATE aimed to examine the effect of high-dose
vitamin D3 supplementation in patients with chronic
HF secondary to LVSD who underwent optimal med-
ical therapy. The results demonstrate that 4,000 IU
vitamin D3 given for 12 months is safe, well tolerated,
and not associated with concerning adverse bio-
chemical effects (Central Illustration).
There was no effect of vitamin D supplementation
on the primary endpoint of 6MWT distance but there
were statistically signiﬁcant and prognostically and
clinically relevant improvements in the secondaryoutcomes of LVEF and LV dimensions and volumes,
thus suggesting that vitamin D is leading to beneﬁcial
reverse remodeling.
New therapies for serious chronic conditions
including chronic HF are often expensive, increasingly
technical, and frequently fail to meet the rigorous
demands of large phase 3 clinical trials. Vitamin D
might be an inexpensive and safe additional option for
chronic HF patients andmay have beneﬁcial effects on
multiple features of the syndrome (13).
Patients with chronic HF are frequently deﬁcient in
vitamin D, and low vitamin D levels increase the risk
of incident chronic HF (26), and are associated with
more severe disease and worse outcomes in patients
with chronic HF (6–9,12). Supplementation to treat or
FIGURE 2 Median and Interquartile Ranges for Vitamin D, Creatinine, Calcium, and Parathyroid Concentrations at 3 Monthly Time Points
in VINDICATE by Treatment Allocation
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Vitamin D concentrations are described in relation to deﬁciency (green line), sufﬁciency (orange line), and the accepted upper limit for
hypervitaminosis D (red line). Serum calcium levels are described in relation to upper limit of normal range (red line), and serum parathyroid
hormone concentrations in relation to the normal range (between red lines). Conversion factors: vitamin D nmol/l $ 0.4 ¼ ng/ml; creatinine
mmol/l $ 0.11 ¼mg/dl; calcium mmol/l $ 4 ¼mg/dl; parathyroid hormone pmol/l $ 9.4 ¼ pg/ml. VINDICATE ¼ VitamIN D treatIng patients with
Chronic heArT failurE.
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FIGURE 3 Median and Interquartile Ranges for 6-Minute Walk Test Distance, and LVEF, LVEDD, and LVEDV Measured by
Echocardiography at Baseline and Final Visit in VINDICATE by Treatment Allocation
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LVEDD ¼ left ventricular end-diastolic dimension; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction;
VINDICATE ¼ VitamIN D treatIng patients with Chronic heArT failurE.
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2599prevent osteoporotic fractures might be associated
with a lower incidence of chronic HF (10).
However, despite the publication of studies
exploring various doses and forms of vitamin Dsupplementation in patients with chronic HF, there
remains considerable uncertainty regarding the ben-
eﬁts of this therapeutic approach. In the ﬁrst study by
Schleithoff et al. (15), 93 subjects received 50 mg
TABLE 2 Change in Primary and Secondary Outcome Variables in VINDICATE at
12 Months Post-Randomization: Intention-to-Treat Population
Endpoint
Randomized
Treatment
Mean Change
After 12 Months
ANCOVA
Difference in
Mean Change p Value
Primary outcome
6-min walk
distance, m
Placebo 10.10 (-20.77 to 40.96) -24.11 (-65.81 to 17.60) 0.255
Vitamin D -12.56 (-40.80 to 15.68)
Secondary outcomes
LVEF, % Placebo 1.36 (-0.38 to 3.11) 6.07 (3.20 to 8.94) <0.001
Vitamin D 7.65 (5.21 to 10.09)
LVEDD, mm Placebo -0.08 (-1.25 to 1.10) -2.49 (-4.09 to -0.90) 0.002
Vitamin D -2.45 (-3.70 to -1.21)
LVESD, mm Placebo -0.99 (-2.31 to 0.33) -2.09 (-4.11 to -0.06) 0.043
Vitamin D -2.72 (-4.52 to -0.92)
LVEDV, ml Placebo -3.83 (-13.36 to 5.70) -13.11 (-25.63 to -0.60) 0.040
Vitamin D -16.47 (-25.71 to -7.22)
LVESV, ml Placebo -8.49 (-17.98 to 1.01) -12.65 (-24.76 to -0.54) 0.041
Vitamin D -18.77 (-25.96 to -9.59)
Values are mean change (95% conﬁdence intervals); 95% signiﬁcance shown in bold.
ANCOVA ¼ analysis of covariance; other abbreviations as in Table 1.
CENTRAL ILLUSTRATION Vitamin D in Chronic Heart Fa
and Function
Witte, K.K. et al. J Am Coll Cardiol. 2016;67(22):2593–603.
Vitamin D improves left ventricular ejection fractions and reduces left ventricular di
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placebo þ Ca2þ. There was a trend to improvement of
LV function measured by echocardiography and a
smaller increase in pro-inﬂammatory cytokines dur-
ing follow-up in those randomized to vitamin D. Both
groups were given Ca2þ and both groups had some
improvement in LV function with no differences be-
tween them. Witham et al. (16) examined vitamin D2
supplementation in 105 elderly patients. Subjects
were randomized to 2 doses of 100,000 IU of vitamin
D2 or placebo at baseline and 10 weeks and assessed
at 20 weeks. There was no effect on walk distance or
immune function, and a slight deterioration in quality
of life. The population in that study was heteroge-
neous; patients with and without LVSD were
included, mean N-terminal B-type natriuretic peptide
levels and daily furosemide doses were lower than
those seen in a usual HF population, medical therapy
was not optimized, the duration of treatment was
short, patients who were randomized to vitamin D
remained deﬁcient (43.4 nmol/l [17.4 ng/ml]),
and PTH was not suppressed (27). Although Boxerilure: Impact on Left Ventricular Structure
mensions and volumes.
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2601et al. (28,29) did not demonstrate improvements in
cardiac function or objective measures of muscle
strength and exercise capacity in 64 chronic HF
patients (of whom 34 underwent echocardiography)
randomized to weekly doses of 50,000 IU of vitamin
D3 for 6 months, there was an improvement in serum
aldosterone and quality of life in those allocated the
supplement. In an open-label study, Schroten et al.
(30) demonstrated a reduction in plasma renin con-
centration after 6 weeks of 2,000 IU vitamin D3 daily
in 101 patients with chronic HF. Finally, Dalbeni et al.
(31) noted an increase in LVEF of almost 7% after only
25 weeks in 13 patients randomized to 600,000 IU
vitaminD3 at baseline and 2 further doses of 100,000 IU
at 10 weeks and 20 weeks, whereas 10 patients ran-
domized to placebo had a reduction in LVEF of more
than 4%. The authors did not comment on cardiac di-
mensions and there was an increase in natriuretic
peptide levels in both groups. In contrast to these
studies, VINDICATE is a double-blind, placebo-
controlled study of an oral noncalcium-based daily
supplement of 4,000 IU of vitamin D3 administered for
12 months in patients with chronic HF due to LVSD on
otherwise optimal medical therapy. The supplement
led to consistent biochemical evidence of replenish-
ment and an effective suppression of PTH levels.
The primary endpoint of VINDICATE was change in
6MWT distance. The study was based upon pilot
data and powered to detect a 28-m difference be-
tween the 2 groups at 12 months (19). The variability
in the walk distance measure at baseline was much
greater than predicted from our pilot study, such that
our sample size only had 7% post hoc power to detect
a difference between the groups. VINDICATE was
therefore underpowered to detect a clinically relevant
change in walk distance. Six-minute walk distance is
an increasingly frequently used patient-oriented
outcome measure, but has greater variability than
objective surrogate endpoints (20). The ﬁndings from
VINDICATE have implications for future studies using
6-min walk distance as an outcome measure.
However, our secondary endpoints of cardiac
function and structure measured by echocardiogra-
phy were highly statistically and clinically signiﬁcant,
with improvements in LVEF, and LV dimensions and
volumes. Similar changes were seen in a subgroup of
patients agreeing to serial CMR imaging, although
they did not reach conventional levels of statistical
signiﬁcance due to lack of power.
A pathophysiological hallmark of chronic HF sec-
ondary to LVSD is a progressive increase in LV cavity
dimensions and impaired contractility, a process
known as LV remodeling (32). Current accepted ther-
apies for chronic HF which afford HF patientsimprovements in survival such as angiotensin con-
verting enzyme inhibitors (33), beta-adrenoceptor
antagonists (34,35), and cardiac resynchronization
therapy (36) have also been shown to have a favorable
effect on LV remodeling by delaying progression of, or
reversing LV dilatation. The degree of favorable
remodeling induced by these treatments is related to
long-term outcomes (37). It is therefore plausible that
the improvements in cardiac function demonstrated in
VINDICATE have the potential to improve outcomes.
HOW DOES VITAMIN D CONTRIBUTE TO BENEFICIAL
REMODELING? Vitamin D deﬁciency could contribute
to adverse remodeling through 2 major pathways.
Vitamin D deﬁciency could lead to cardiomyocyte
dysfunction by interfering with Ca2þ transport (38) at a
cellular concentration. HF is a condition of intracel-
lular calcium overload that adversely affects both
contraction and relaxation. Furthermore, vitamin D
deﬁciency might contribute to cardiomyocyte hyper-
trophy, interstitial inﬂammation, and ﬁbrosis (39).
Hence, vitamin D deﬁciency could contribute to amore
rapid progression to HF following myocardial damage
due to more aggressive adverse remodeling (40).
However, adverse remodeling is also the result of
persistent neurohormonal activation, particularly that
of the renin angiotensin aldosterone system (RAAS)
which strongly contributes to deteriorating cardiac
function, cardiomyocyte loss, and interstitial ﬁbrosis
(41). Inhibition of the RAAS leads to attenuated or
reverse LV remodeling in patients with HF (42).
Vitamin D deﬁciency heightens RAAS activity (30,43),
whereas vitamin D supplementation seems to reduce
renin synthesis (44) and plasma renin activity (43).
STUDY LIMITATIONS. VINDICATE was performed at a
single center. However, the study was based upon re-
sults from a randomized, placebo-controlled pilot
study in 53 patients using the same dose for 12 months
that also showed a favorable effect of vitamin D on
cardiac structure and function (19).Wedidnot examine
the effect of vitamin D supplementation in patients
with chronic HF and preserved ejection fraction, a
group of patients whomaywarrant such investigation.
CONCLUSIONS
VINDICATE has demonstrated that high-dose vitamin
D3 supplementation is safe, well-tolerated, and asso-
ciated with a clinically relevant improvement in car-
diac function in chronic HF patients already taking
current optimal therapies.
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